3352 STT3/PglB/AglB transmembrane domain
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Lipids and lipid-like molecules | 5 | 0.7 | 7.59× | not tested | |
| Organic nitrogen compounds | 1 | 0.2 | 5.30× | not tested | |
| Organoheterocyclic compounds | 2 | 0.9 | 2.20× | not tested | |
| Homogeneous metal compounds | 6 | 2.9 | 2.07× | not tested | |
| Organic oxygen compounds | 1 | 1.2 | 0.85× | not tested | |
| Homogeneous non-metal compounds | 1 | 1.3 | 0.79× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02306 | CPL | Palmitoyl-Linoleoyl Phosphatidylcholine | 3 |
| DB03831 | MPG | [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate | 2 |
| DB00141 | NAG | N-Acetylglucosamine | 1 |
| DB03945 | PC | N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium | 1 |
| DB04327 | PEE | Phosphatidylethanolamine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MNmetal | MANGANESE (II) ION | 6 |
| CPL | 1-PALMITOYL-2-LINOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 5 |
| MGmetal | MAGNESIUM ION | 5 |
| 9UB | [(2~{S},3~{R},4~{R},5~{S},6~{R})-3-acetamido-6-(hydroxymethyl)-4,5-bis(oxidanyl)oxan-2-yl]methyl-[oxidanyl-[(2~{Z},6~{Z},10~{Z})-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoxy]phosphoryl]oxy-phosphinic acid | 4 |
| EGY | (4R,7R)-4-hydroxy-N,N,N-trimethyl-4,9-dioxo-7-[(undecanoyloxy)methyl]-3,5,8-trioxa-4lambda~5~-phosphadocosan-1-aminium | 4 |
| ELU | phosphono [(3~{R},6~{E},10~{E})-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl] hydrogen phosphate | 4 |
| KZB | (2~{S},3~{R},4~{R},5~{S},6~{S})-2-(hydroxymethyl)-6-[(1~{S},2~{R},3~{R},4~{R},5'~{S},6~{S},7~{R},8~{S},9~{R},12~{R},13~{R},15~{S},16~{S},18~{R})-5',7,9,13-tetramethyl-3,15-bis(oxidanyl)spiro[5-oxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosane-6,2'-oxane]-16-yl]oxy-oxane-3,4,5-triol | 4 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 4 |
| 323 | 2-[3,6-bis(dimethylamino)xanthen-9-yl]-5-methanoyl-benzoate | 2 |
| CL | CHLORIDE ION | 2 |
| MJC | dolichyl phosphate mannose | 2 |
| MPG | [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate | 2 |
| NAmetal | SODIUM ION | 2 |
| ZNmetal | ZINC ION | 2 |
| 0K3 | (2Z,6Z,10Z,14Z,18Z,22Z,26Z)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl dihydrogen phosphate | 1 |
| 5TR | [(2~{E},6~{E},10~{E},14~{E},18~{Z},22~{E},26~{Z},30~{E},34~{E},38~{E})-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl] dihydrogen phosphate | 1 |
| 7E8 | (2R)-2,3-DIHYDROXYPROPYL (7Z)-TETRADEC-7-ENOATE | 1 |
| A1A7X | 2-deoxy-2-fluoro-1-O-[(S)-hydroxy{[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}phosphoryl]-beta-D-arabinofuranose | 1 |
| A1I0M | dolichol-phosphate (n=4) | 1 |
| A1I0N | dolichol-phosphate-mannose (n=2) | 1 |